ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $880,000 | +10.6% | 15,489 | -14.4% | 0.05% | +14.0% |
Q2 2021 | $796,000 | -18.2% | 18,091 | -8.3% | 0.04% | -23.2% |
Q1 2021 | $973,000 | +19.4% | 19,724 | +1.8% | 0.06% | -5.1% |
Q4 2020 | $815,000 | -59.5% | 19,366 | -55.9% | 0.06% | -9.2% |
Q3 2020 | $2,010,000 | -64.2% | 43,902 | -60.7% | 0.06% | -55.2% |
Q2 2020 | $5,612,000 | -13.0% | 111,769 | -10.9% | 0.14% | -14.7% |
Q1 2020 | $6,453,000 | -24.3% | 125,472 | -9.1% | 0.17% | +41.7% |
Q4 2019 | $8,524,000 | +3757.0% | 137,980 | +3647.4% | 0.12% | +3900.0% |
Q3 2019 | $221,000 | -57.0% | 3,682 | -39.6% | 0.00% | -70.0% |
Q2 2019 | $514,000 | +18.2% | 6,095 | +33.8% | 0.01% | +11.1% |
Q1 2019 | $435,000 | +75.4% | 4,556 | +30.1% | 0.01% | +80.0% |
Q4 2018 | $248,000 | -38.0% | 3,502 | -25.1% | 0.01% | -37.5% |
Q3 2018 | $400,000 | -91.8% | 4,677 | -88.9% | 0.01% | -93.5% |
Q2 2018 | $4,869,000 | +1161.4% | 42,007 | +779.5% | 0.12% | +1027.3% |
Q1 2018 | $386,000 | – | 4,776 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |